Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Top Ranked Growth Stocks to Buy for February 10th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 10th

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to Q4 Earnings?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

Palatin (PTN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.

Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.

Merck (MRK) Q4 Earnings & Sales Miss, CEO Frazier Steps Down

by Zacks Equity Research

Merck (MRK) misses Q4 estimates for earnings and sales. CEO Kenneth C. Frazier, to retire.

Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Alexion (ALXN)

by Zacks Equity Research

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sanghamitra Saha headshot

5 Top-Ranked Stocks Likely to Beat Earnings Estimates

by Sanghamitra Saha

These top-ranked stocks are likely to beat on bottom line in their next releases.

Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes

by Zacks Equity Research

Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.

Will Eylea, Dupixent Drive Regeneron's (REGN) Q4 Earnings?

by Zacks Equity Research

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports fourth-quarter 2020 results.

What's in Store for Innoviva (INVA) This Earnings Season?

by Zacks Equity Research

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.

What's in the Cards for Bristol-Myers' (BMY) Q4 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter 2020 results.

Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib

by Zacks Equity Research

Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.

Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.

Illumina (ILMN) New Collaboration to Aid Genomics Startups

by Zacks Equity Research

Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.

Kinjel Shah headshot

5 Promising Price-to-Book Value Stocks to Buy Now

by Kinjel Shah

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.

Zacks.com featured highlights include: Vale, Canadian Solar, Alexion Pharmaceuticals and Affiliated Managers Group

by Zacks Equity Research

Zacks.com featured highlights include: Vale, Canadian Solar, Alexion Pharmaceuticals and Affiliated Managers Group

Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.

Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance

by Zacks Equity Research

Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.

Sumit Singh headshot

Add These 4 Low P/CF Stocks to Portfolio for Optimum Returns

by Sumit Singh

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Canadian Solar (CSIQ), Alexion Pharmaceuticals (ALXN), Vale S.A. (VALE) and Affiliated Managers Group (AMG) boast low P/CF ratio.

What's in the Cards for HCA Healthcare (HCA) Q4 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) fourth-quarter earnings are likely to have witnessed better patient volumes and improved revenues.

Alexion Pharmaceuticals (ALXN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Encompass Health (EHC) Q4 Earnings Beat Estimates, Rise Y/Y

by Zacks Equity Research

Encompass Health's (EHC) fourth-quarter results gain from improved revenues and lower costs, partly offset by lower volumes in both its segments.

Global Blood's (GBT) MAA for Oxbryta Accepted in Europe

by Zacks Equity Research

Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.